Uterine cancer remains a critical health issue worldwide, particularly when it comes to accessibility and equitable care for all women. Yasmine Hassan, who serves as AstraZeneca’s Director of Global Oncology Policy, Advocacy, and Health Equity, recently highlighted the pressing need to address these disparities.
In a LinkedIn post, she stated, “If detected early, uterine cancer can have a 95% 5-year survival rate. But for women diagnosed late, survival rates may fall below 20%.” This stark contrast underscores the crucial role early diagnosis plays in improving outcomes. Unfortunately, various barriers—including inadequate diagnostic tools, restricted access to healthcare professionals, and financial limitations—create a significant chasm in care across different regions.
Hassan stresses that it’s unacceptable for survival rates to be influenced by factors such as location, income, or societal stigma surrounding gynecological health. As such, she calls for urgent action to include uterine cancer in global health discussions.
Global Focus on Noncommunicable Diseases
The ongoing United Nations General Assembly High-Level Meeting places noncommunicable diseases, including cancers like uterine cancer, firmly in the spotlight. This initiative marks a significant move towards achieving health equity on a global scale. As discussions progress, it is essential to ensure that uterine cancer is prioritized so that no woman is overlooked.
Key Priorities for Action
During the 2025 Concordia Annual Summit, a position paper titled “Spotlight on Uterine Cancer: Shaping Access to Equitable and High-Quality Care,” supported by AstraZeneca, was introduced. This document outlines key priorities necessary for improving care for women affected by this disease:
- Addressing the stigma that prevents women from seeking care
- Investing in diagnostic infrastructure and molecular testing
- Expanding equitable access to a variety of care options
- Integrating uterine cancer into both global and national health agendas
Collaborative Efforts for Change
A coalition of organizations, including the International Gynecologic Cancer Society, European Society of Gynaecological Oncology (ESGO), Society of Gynecologic Oncology, and several others, have joined forces with AstraZeneca on this initiative. Their collective goal is to ensure that women at risk of, or currently living with, uterine cancer receive the care they deserve.
The Path Forward
Ultimately, every woman should have the opportunity for early diagnosis and high-quality care. To truly make a difference in the fight against uterine cancer, the healthcare community must unite and advocate for policies that prioritize women’s health.
As we move forward, it is vital to keep raising awareness and pushing for systemic changes that will bring uterine cancer—and women’s health more broadly—out of the shadows and into public consciousness.
For more insights on this critical issue, further details can be found in AstraZeneca’s global statement.
